[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410196":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":57,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":21,"enrollmentInfo":73,"targetDuration":21,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":40,"whyStopped":21,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient with intracerebral haemorrhage","EXPERIMENTAL","Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.",[13,14],"Radiation: Brain MRI","Biological: Biological biomarkers",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","Brain MRI","Brain MRI will include differents sequences.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"BIOLOGICAL","Biological biomarkers","Biological biomarkers will include a set of systemic inflammatory markers",[9],[28],{"name":29,"affiliation":5,"role":30},"Charlotte Cordonnier, MD,PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","0320445962","+33","charlotte.cordonnier@chu-lille.fr",[38],{"facility":39,"status":40,"city":41,"state":21,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"CHU de Lille","RECRUITING","Lille","59037","France","FR",{"type":46,"coordinates":47},"Point",[48,49],3.05512,50.63391,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":54,"phoneExt":35,"email":36},"CORDONNIER Charlotte, MHD, PHD","0320446814",{"type":56,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[58,61],{"name":59,"class":60},"Conseil Régional Hauts-de-France, France","UNKNOWN",{"name":62,"class":60},"Fondation pour la recherche sur les AVC","100410196","influence-of-cerebral-oedema-in-intracerebral-haemorrhage-100410196",false,"NCT04621357","Influence of Cerebral Oedema in Intracerebral Haemorrhage","Consequences of Oedema on the Prognosis of InTraCerebral Haemorrhage","COPITCH","Inclusion Criteria:\n\n* With a spontaneous ICH, i.e. non traumatic\n* Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset\n* Patient insured under the French social security\n* Consent form signed\n\nExclusion Criteria:\n\n* Pure intraventricular haemorrhages\n* \"secondary\" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct\n* Pre-admission modified Rankin score of 4 or 5\n* Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)\n* Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)\n* Adults who are deprived of their liberty by judicial or administrative decision\n* Referral from other hospitals\n* Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms; gadolinium allergy\n* No consent form","ALL","18 Years",{"count":74,"type":75},500,"ESTIMATED","INTERVENTIONAL",[78],"NA","In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history as well as the clinical impact of this PHO remain unclear. The COPITCH study has been designed to answer these questions",[81,82],"Stroke","Intra Cerebral Hemorrhage",[82,84,85,86],"Perihaematomal oedema","MRI","outcome","2026-04-17",{"date":89,"type":90},"2026-04-22","ACTUAL",{"date":92,"type":90},"2021-06-04",{"date":94,"type":75},"2027-12-03",{"name":5,"class":6},1]